Nintedanib 150 mg serves as an authorized treatment option for patients suffering from severe progressive lung diseases which include idiopathic pulmonary fibrosis and systemic sclerosis-associated interstitial lung disease and other fibrosing interstitial lung disorders. The diseases produce lung tissue scarring which results in diminished oxygen exchange and breathing difficulties. The active ingredient Nintedanib 150 mg helps to reduce the scarring process while maintaini